Cue Biopharma Has Completed Patient Enrollment In Its Phase 1 Trial Of CUE-101 In Combination With Keytruda (Pembrolizumab) As First-line Treatment For Human Papilloma Virus Positive Recurrent/Metastatic Head And Neck Squamous Cell Carcinoma
Portfolio Pulse from Benzinga Newsdesk
Cue Biopharma has completed patient enrollment in its Phase 1 trial of CUE-101 in combination with Keytruda as a first-line treatment for HPV positive recurrent/metastatic head and neck squamous cell carcinoma.
September 26, 2023 | 12:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cue Biopharma's completion of patient enrollment for its Phase 1 trial of CUE-101 could potentially accelerate the drug's development timeline.
The completion of patient enrollment for a clinical trial is a significant milestone in drug development. It suggests that the trial is progressing as planned, which could potentially accelerate the timeline for the drug's development and eventual approval. This could have a positive impact on Cue Biopharma's stock in the short term.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100